News
All →Publications
All →
WHO’s Department of Regulation and Prequalification strategic action plan (2025–2028) sets out the five strategic priorities that will enable...

Protocol on estimation of Guillain-Barré syndrome background rates in general population in low- and...
Background rates of possible adverse events are crucial to monitoring vaccine safety as they help separate potential safety signals following vaccination...

WHO Global Network of National Quality Control Laboratories for Pharmaceuticals: first meeting report,...
The first annual meeting of the World Health Organization (WHO) Global Network of Quality Control Laboratories for Pharmaceuticals (WHO-GNP) was organized...

The Local Production and Assistance (LPA) Unit in the Regulation and Prequalification Department (RPQ), Access to Medicines and Health Products Division...
Related documents

Greener Pharmaceuticals' Regulatory Highway

An effective regulatory system plays a critical role in ensuring the quality of health products, spanning from their development in the laboratory to their...
Newsletters
All →
WHO pharmaceuticals newsletter - No. 1, 2025
The WHO pharmaceuticals newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities...

Report of the 4th joint meeting of the WHO Global Advisory Committee on Vaccine Safety and the Advisory...
The Global Advisory Committee on Vaccine Safety (GACVS) was established in 1999, and the Advisory Committee on Safety of Medicinal Products (ACSoMP)...